Browsing Tag
Neuphoria Therapeutics
3 posts
Neuphoria Therapeutics shares jumped while Scancell plunged, and the merger terms explain why
Scancell’s Neuphoria Therapeutics merger unlocks Nasdaq access and up to $89 million, but dilution and debt reshape the iSCIB1+ outlook.
Scancell Holdings (LSE:SCLP): Can a Nasdaq deal fund its pivotal melanoma trial?
Scancell has strong melanoma data, but Phase 3 still needs funding. A Nasdaq deal could reset LSE:SCLP, or leave investors facing dilution and deal risk.
Neuphoria Therapeutics secures milestone payment from Merck as Alzheimer’s clinical trial advances
Neuphoria Therapeutics Inc. (Nasdaq: NEUP), a late-stage biotechnology company focused on developing treatments for neuropsychiatric disorders, has announced…